Chattha Anmol, Brown Emile, Slavin Sumner, Lin Samuel
Division of Plastic and Reconstructive Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Aesthet Surg J. 2018 Feb 15;38(3):NP56-NP60. doi: 10.1093/asj/sjx234.
Oral contraceptive pills (OCPs) are currently used by approximately 16% of all women aged 15 to 44 in the United States and have been used by 80% of all sexually active women at some point in their lives. However, no guidelines exist for discontinuation of OCP therapy before or after elective cosmetic surgery.
The aim of this study is to establish current practice trends regarding perioperative OCP management in aesthetic surgery.
An eight-item online survey was distributed to members of the American Society of Plastic Surgeons (ASPS). Survey results were analyzed to determine if surgeons' practice setting, years of experience, annual cosmetic volume, or types of cosmetic procedures performed affected their perioperative management of OCPs.
A total of 220 questionnaires were collected (11.9% response rate). Only 31.8% of surgeons reported any discontinuation of OCPs pre- or postoperatively. Among physicians, 7.3% reported only preoperative discontinuation, 24.5% reported OCP discontinuation both pre- and postoperatively, and 0.0% of physicians reported discontinuation of OCPs only postoperatively. There was no statistically significant difference between the percentage of surgeons in academic practice who discontinue OCPs perioperatively (P = 0.335). There was no statistical significance towards overall years in practice (P = 0.152). There were no significant differences between the three groups in the number of cosmetic procedures performed annually or percentage breakdown of procedures performed.
Despite OCP therapy being a known risk factor for venous thromboembolic events, a majority of surgeons performing cosmetic surgery do not routinely recommend perioperative cessation.
在美国，目前约16%的15至44岁女性使用口服避孕药（OCPs），且80%的性活跃女性在其生命中的某个阶段曾使用过。然而，对于择期整容手术前后停用OCP治疗，尚无相关指南。
本研究的目的是确定美容手术围手术期OCP管理的当前实践趋势。
向美国整形外科医师协会（ASPS）成员发放了一份包含八个项目的在线调查问卷。对调查结果进行分析，以确定外科医生的执业环境、从业年限、年度整容手术量或所实施的整容手术类型是否会影响他们对OCPs的围手术期管理。
共收集到220份问卷（回复率为11.9%）。只有31.8%的外科医生报告在术前或术后停用了OCPs。在医生中，7.3%仅报告术前停用，24.5%报告术前和术后均停用OCPs，0.0%的医生仅报告术后停用OCPs。学术机构的外科医生围手术期停用OCPs的比例之间无统计学显著差异（P = 0.335）。在总体执业年限方面无统计学意义（P = 0.152）。三组在每年进行的整容手术数量或所实施手术的百分比细分方面无显著差异。
尽管OCP治疗是静脉血栓栓塞事件的已知风险因素，但大多数进行整容手术的外科医生并不常规建议围手术期停药。
